Shiyu Zhang1, Jiaxing Song2, Yuyan Yang3, Huilei Miao3, Lu Yang1, Yuehua Liu1, Xue Zhang2, Yaping Liu4, Tao Wang5. 1. Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. 2. Department of Medical Genetics and National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, China. 3. Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. 4. Department of Medical Genetics and National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, China. ypliu@ibms.pumc.edu.cn. 5. Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. wangtaopumch@126.com.
Abstract
BACKGROUND: Type I interferonopathies are a group of rare autoimmune diseases characterised by excessive activation of type I interferon that leads to disturbances in immune function. Three prime repair exonuclease 1 (TREX1) is an important exonuclease and plays an important role in DNA damage repair. TREX1 mutations are associated with many type I interferonopathies. Studies have been published on the effectiveness of tofacitinib in the treatment of type I interferonopathies. The aim of this study is to identify the pathogenic variation in a Chinese family with type I interferonopathies and to observe the therapeutic effects of tofacitinib. METHODS: A Chinese family with two members with type I interferonopathies was investigated. Whole exome sequencing and Sanger sequencing were applied for mutation screening using peripheral blood DNA of the patient and her family members. Sequencing results were analysed using bioinformatics software tools including VarCards and PolyPhen-2. Close clinical follow-up and observation were used to record changes in the disease before and after treatment with tofacitinib. RESULTS: Compound heterozygous variants of TREX1 were observed in the patient's genome. One was a missense variant (NM_016381; c.C227T; p.Ala76Val) from the patient's father, and the other was a frameshift variant (NM_016381; c.458dupA; p.Gln153Glnfs*3) from the patient's mother. One of the proband's elder brothers with similar skin lesions also carried these two variants. This brother of the proband had more serious cutaneous involvement with the comorbidity of cerebral palsy. These TREX1 variants have not been reported in previous studies and are predicted to be highly pathogenic. The proband was given tofacitinib that led to a marked improvement. CONCLUSIONS: We identified two novel complex heterozygous variants in the TREX1 gene, which may underlie the molecular pathogenesis of the type I interferonopathies observed in members of this family. Tofacitinib could be an alternative treatment for this disease.
BACKGROUND: Type I interferonopathies are a group of rare autoimmune diseases characterised by excessive activation of type I interferon that leads to disturbances in immune function. Three prime repair exonuclease 1 (TREX1) is an important exonuclease and plays an important role in DNA damage repair. TREX1 mutations are associated with many type I interferonopathies. Studies have been published on the effectiveness of tofacitinib in the treatment of type I interferonopathies. The aim of this study is to identify the pathogenic variation in a Chinese family with type I interferonopathies and to observe the therapeutic effects of tofacitinib. METHODS: A Chinese family with two members with type I interferonopathies was investigated. Whole exome sequencing and Sanger sequencing were applied for mutation screening using peripheral blood DNA of the patient and her family members. Sequencing results were analysed using bioinformatics software tools including VarCards and PolyPhen-2. Close clinical follow-up and observation were used to record changes in the disease before and after treatment with tofacitinib. RESULTS: Compound heterozygous variants of TREX1 were observed in the patient's genome. One was a missense variant (NM_016381; c.C227T; p.Ala76Val) from the patient's father, and the other was a frameshift variant (NM_016381; c.458dupA; p.Gln153Glnfs*3) from the patient's mother. One of the proband's elder brothers with similar skin lesions also carried these two variants. This brother of the proband had more serious cutaneous involvement with the comorbidity of cerebral palsy. These TREX1 variants have not been reported in previous studies and are predicted to be highly pathogenic. The proband was given tofacitinib that led to a marked improvement. CONCLUSIONS: We identified two novel complex heterozygous variants in the TREX1 gene, which may underlie the molecular pathogenesis of the type I interferonopathies observed in members of this family. Tofacitinib could be an alternative treatment for this disease.
Authors: Hanna Kim; Kristina M Brooks; Cheng Cai Tang; Paul Wakim; Mary Blake; Stephen R Brooks; Gina A Montealegre Sanchez; Adriana A de Jesus; Yan Huang; Wanxia Li Tsai; Massimo Gadina; Apurva Prakash; Jonathan Marcus Janes; Xin Zhang; William L Macias; Parag Kumar; Raphaela Goldbach-Mansky Journal: Clin Pharmacol Ther Date: 2017-12-08 Impact factor: 6.875
Authors: Anna Richards; Arn M J M van den Maagdenberg; Joanna C Jen; David Kavanagh; Paula Bertram; Dirk Spitzer; M Kathryn Liszewski; Maria-Louise Barilla-Labarca; Gisela M Terwindt; Yumi Kasai; Mike McLellan; Mark Gilbert Grand; Kaate R J Vanmolkot; Boukje de Vries; Jijun Wan; Michael J Kane; Hafsa Mamsa; Ruth Schäfer; Anine H Stam; Joost Haan; Paulus T V M de Jong; Caroline W Storimans; Mary J van Schooneveld; Jendo A Oosterhuis; Andreas Gschwendter; Martin Dichgans; Katya E Kotschet; Suzanne Hodgkinson; Todd A Hardy; Martin B Delatycki; Rula A Hajj-Ali; Parul H Kothari; Stanley F Nelson; Rune R Frants; Robert W Baloh; Michel D Ferrari; John P Atkinson Journal: Nat Genet Date: 2007-07-29 Impact factor: 38.330
Authors: Gina A Montealegre Sanchez; Adam Reinhardt; Suzanne Ramsey; Helmut Wittkowski; Philip J Hashkes; Yackov Berkun; Susanne Schalm; Sara Murias; Jason A Dare; Diane Brown; Deborah L Stone; Ling Gao; Thomas Klausmeier; Dirk Foell; Adriana A de Jesus; Dawn C Chapelle; Hanna Kim; Samantha Dill; Robert A Colbert; Laura Failla; Bahar Kost; Michelle O'Brien; James C Reynolds; Les R Folio; Katherine R Calvo; Scott M Paul; Nargues Weir; Alessandra Brofferio; Ariane Soldatos; Angelique Biancotto; Edward W Cowen; John J Digiovanna; Massimo Gadina; Andrew J Lipton; Colleen Hadigan; Steven M Holland; Joseph Fontana; Ahmad S Alawad; Rebecca J Brown; Kristina I Rother; Theo Heller; Kristina M Brooks; Parag Kumar; Stephen R Brooks; Meryl Waldman; Harsharan K Singh; Volker Nickeleit; Maria Silk; Apurva Prakash; Jonathan M Janes; Seza Ozen; Paul G Wakim; Paul A Brogan; William L Macias; Raphaela Goldbach-Mansky Journal: J Clin Invest Date: 2018-06-11 Impact factor: 14.808
Authors: Alice Verdelli; Alberto Corrà; Elena Biancamaria Mariotti; Cristina Aimo; Valentina Ruffo di Calabria; Walter Volpi; Lavinia Quintarelli; Marzia Caproni Journal: Front Med (Lausanne) Date: 2022-09-23